NCT06143371CompletedPhase 1
A Phase I (First-in-Human) Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CAN10, an Anti-IL1RAP Monoclonal Antibody, in Healthy Subjects and in Subjects with Mild to Moderate Plaque Psoriasis
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Dec 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 112 (actual)
- First submitted
- 20 Apr 2023
- Start date
- 21 Aug 2023
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization Inc.
- Diseases
- Psoriasis
- NCT number
- NCT06143371
- EU CT number
- 2023-504450-35-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 112
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CRS Clinical Research Services Management GmbH Coordinator of this site? Confirm its status | Berlin | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.